Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019693 (
HIV
)
170,526
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The budding of many enveloped RNA viruses, including human immunodeficiency virus type 1 (HIV-1), requires some of the same cellular machinery as vesicle formation at the multivesicular body (MVB). In Saccharomyces cerevisiae, the ESCRT-II complex performs a central role in MVB protein sorting and vesicle formation, as it is recruited by the upstream ESCRT-I complex and nucleates assembly of the downstream ESCRT-III complex. Here, we report that the three subunits of human ESCRT-II, EAP20, EAP30, and EAP45, have a number of properties in common with their yeast orthologs. Specifically, EAP45 bound
ubiquitin
via its N-terminal GRAM-like
ubiquitin
-binding in EAP45 (GLUE) domain, both EAP45 and EAP30 bound the C-terminal domain of TSG101/ESCRT-I, and EAP20 bound the N-terminal half of CHMP6/ESCRT-III. Consistent with its expected role in MVB vesicle formation, (i) human ESCRT-II localized to endosomal membranes in a VPS4-dependent fashion and (ii) depletion of EAP20/ESCRT-II and CHMP6/ESCRT-III inhibited lysosomal targeting and downregulation of the epidermal growth factor receptor, albeit to a lesser extent than depletion of TSG101/ESCRT-I. Nevertheless,
HIV
-1 release and infectivity were not reduced by efficient small interfering RNA depletion of EAP20/ESCRT-II or CHMP6/ESCRT-III. These observations indicate that there are probably multiple pathways for protein sorting/MVB vesicle formation in human cells and that
HIV
-1 does not utilize an ESCRT-II-dependent pathway to leave the cell.
...
PMID:Human ESCRT-II complex and its role in human immunodeficiency virus type 1 release. 1697 52
In a genome-wide analysis, we have identified 85 human genes encoding 103 protein isoforms that resemble retroviral Gag proteins. These genes were domesticated from retrotransposons in at least five independent events during vertebrate evolution and were subsequently duplicated further in mammals. Structural insights into the mammalian proteins can be inferred by homology to Gag from viruses such as
HIV
; in turn, the cellular roles of the mammalian Gag homologs, such as apoptosis-related functions and binding to
ubiquitin
ligases, might hint at further functionality of viral Gag itself.
...
PMID:Computational characterization of multiple Gag-like human proteins. 1697 84
Retroviral aspartyl proteases are homodimeric, whereas eukaryotic aspartyl proteases tend to be large, monomeric enzymes with 2-fold internal symmetry. It has been proposed that contemporary monomeric aspartyl proteases evolved by gene duplication and fusion from a primordial homodimeric enzyme. Recent sequence analyses have suggested that such "fossil" dimeric aspartyl proteases are still encoded in the eukaryotic genome. We present evidence for retention of a dimeric aspartyl protease in eukaryotes. The X-ray crystal structure of a domain of the Saccharomyces cerevisiae protein Ddi1 shows that it is a dimer with a fold similar to that of the retroviral proteases. Furthermore, the double Asp-Thr-Gly-Ala amino acid sequence motif at the active site of
HIV
protease is found with identical geometry in the Ddi1 structure. However, the putative substrate binding groove is wider in Ddi1 than in the retroviral proteases, suggesting that Ddi1 accommodates bulkier substrates. Ddi1 belongs to a family of proteins known as the
ubiquitin
receptors, which have in common the ability to bind ubiquitinated substrates and the proteasome. Ubiquitin receptors contain an amino-terminal
ubiquitin
-like (UBL) domain and a carboxy-terminal
ubiquitin
-associated (UBA) domain, but Ddi1 is the only representative in which the UBL and UBA domains flank an aspartyl protease-like domain. The remarkable structural similarity between the central domain of Ddi1 and the retroviral proteases, in the global fold and in active-site detail, suggests that Ddi1 functions proteolytically during regulated protein turnover in the cell.
...
PMID:Ddi1, a eukaryotic protein with the retroviral protease fold. 1701 Mar 77
The
HIV
-1 Rev protein plays a key role in virus replication by allowing export to the cytoplasm of unspliced or singly-spliced RNAs. In this report, we investigated whether Rev is modified by ubiquitination or sumoylation. Whereas no evidence of sumoylation was obtained, transient expression experiments showed that
ubiquitin
conjugates to Rev as high molecular weight polyubiquitin chains. Mutation of the three lysine residues of Rev showed that the site of
ubiquitin
conjugation is Lys-115. Experiments with
ubiquitin
mutants including a single lysine at every seven possible position indicated that branching of the polyubiquitin chains mainly involves Lys-33. Mutation of Rev Lys-115 to arginine reduces markedly the steady state amount of the protein, but does not impair its ability to export RNA via the Rev response element. These observations support the notion that polyubiquitination of Rev stabilizes the viral protein but hinders its activity.
...
PMID:Modulation of HIV-1 Rev protein abundance and activity by polyubiquitination with unconventional Lys-33 branching. 1706 81
The endosomal sorting complex ESCRT-III, which is formed by the structurally related CHMP proteins, is engaged by
HIV
-1 to promote viral budding. Here we show that progressive truncations into the C-terminal acidic domains of CHMP proteins trigger an increasingly robust anti-
HIV
budding activity. Together with biochemical evidence for specific intramolecular interactions between the basic and acidic halves of CHMP3 and CHMP4B, these results suggest that the acidic domains are autoinhibitory. The acidic half of CHMP3 also interacts with the endosome-associated
ubiquitin
isopeptidase AMSH, and the coexpression of AMSH or its CHMP3-binding domain converts wild-type CHMP3 into a potent inhibitor of
HIV
-1 release. Point mutations in CHMP3 that prevent binding to AMSH abrogate this effect, suggesting that binding to AMSH relieves the autoinhibition of CHMP3. Collectively, our results indicate that CHMP proteins are regulated through an autoinhibitory switch mechanism that allows tight control of ESCRT-III assembly.
...
PMID:Release of autoinhibition converts ESCRT-III components into potent inhibitors of HIV-1 budding. 1714 56
Proteasome plays a key role in antigen presentation through MHC class I pathway. Thus, approaches are actively developed to increase proteasome targeting of DNA-vaccine encoded proteins. Gene of reverse transcriptase of
HIV
-1 is used in DNA-vaccines. It was shown, that revertase degraded in cells slowly (half-life is 18-20 h). Revertase content increased in presence of proteasome inhibitors MG132 and epoxomicin indicated that it degraded by proteasome. Level of protein was 2 fold higher after treatment with MG132 then after epoxomicin treatment. Since epoxomicin is more specific proteasome inhibitor it indicated that other cellular proteases can take part in revertase degradation. With the aim to increase affinity and degradation rate by proteasome of revertase we have to add strong degradation signal. Ornithine decarboxylase contains this kind of signals, it's unique properties are fast degradation by proteasome in
ubiquitin
-independent manner. As result fusion protein of revertase and ornithine decarboxylase was created. Half-life of fusion protein was 6 time less than revertase (3 h). Degradation of fusion protein was blocked by proteasome inhibitors 10 times stronger than revertase. Thus, degradation by proteasome pathway of reverse transcriptase was enhanced by fusion with ornithine decarboxylase. Performance of this fusion could improve presentation of revertase in DNA-vaccine.
...
PMID:[Artifitial increase of HIV-1 reverse transcriptase turnover through proteasome pathway]. 1720 25
Relatively little is known at the functional genomic level about the global host response to human immunodeficiency virus type 1 (HIV-1) infection. Microarray analyses by several laboratories, including our own, have revealed that
HIV
-1 infection causes significant changes in host mRNA abundance and regulation of several cellular biological pathways. However, it remains unclear what consequences these changes bring about at the protein level. Here we report the expression levels of approximately 3,200 proteins in the CD4(+) CEMx174 cell line after infection with the LAI strain of human immunodeficiency virus type 1 (HIV-1); the proteins were assessed using liquid chromatography-mass spectrometry coupled with stable isotope labeling and the accurate mass and time tag approach. Furthermore, we found that 687 (21%) proteins changed in abundance at the peak of virus production at 36 h postinfection. Pathway analysis revealed that the differential expression of proteins was concentrated in select biological pathways, exemplified by
ubiquitin
-conjugating enzymes in ubiquitination, carrier proteins in nucleocytoplasmic transport, cyclin-dependent kinase in cell cycle progression, and pyruvate dehydrogenase of the citrate cycle pathways. Moreover, we observed changes in the abundance of proteins with known interactions with
HIV
-1 viral proteins. Our proteomic analysis captured changes in the host protein milieu at the time of robust virus production, depicting changes in cellular processes that may contribute to virus replication. Continuing analyses are expected to focus on blocking virus replication by targeting these pathways and their effector proteins.
...
PMID:Quantitative analysis of human immunodeficiency virus type 1-infected CD4+ cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production. 1749 70
HIV
-1 Vpr is a viral accessory protein that activates ATR through the induction of DNA replication stress. ATR activation results in cell cycle arrest in G2 and induction of apoptosis. In the present study, we investigate the role of the
ubiquitin
/proteasome system (UPS) in the above activity of Vpr. We report that the general function of the UPS is required for Vpr to induce G2 checkpoint activation, as incubation of Vpr-expressing cells with proteasome inhibitors abolishes this effect. We further investigated in detail the specific E3 ubiquitin ligase subunits that Vpr manipulates. We found that Vpr binds to the DCAF1 subunit of a cullin 4a/DDB1 E3 ubiquitin ligase. The carboxy-terminal domain Vpr(R80A) mutant, which is able to bind DCAF1, is inactive in checkpoint activation and has dominant-negative character. In contrast, the mutation Q65R, in the leucine-rich domain of Vpr that mediates DCAF1 binding, results in an inactive Vpr devoid of dominant negative behavior. Thus, the interaction of Vpr with DCAF1 is required, but not sufficient, for Vpr to cause G2 arrest. We propose that Vpr recruits, through its carboxy terminal domain, an unknown cellular factor that is required for G2-to-M transition. Recruitment of this factor leads to its ubiquitination and degradation, resulting in failure to enter mitosis.
...
PMID:HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. 1755 73
Ubiquitin is important for the release of human immunodeficiency virus 1 (HIV-1) and several other retroviruses. All major domains of the
HIV
-1 Gag protein are monoubiquitinated, but the modifying machinery and the function of
HIV
-1 Gag ubiquitination remain unclear. Here, we show that the induction of a late budding arrest by mutation of the
HIV
-1 PTAP motif or by specific inhibition of selected ESCRT components leads to an increase of Gag-
ubiquitin
conjugates in cells, which coincides with an accumulation of detergent-insoluble, multimerized Gag at the plasma membrane. Membrane flotation experiments revealed that ubiquitinated Gag is highly enriched in membrane-bound fractions. Based on these findings, we propose that a blocking of virus release results in increased Gag ubiquitination as a consequence of its prolonged membrane association. Consistent with this, ubiquitination of a membrane-binding-defective (G2A)Gag mutant was dramatically reduced and the ubiquitination levels of truncated Gag proteins correlated with their abilities to bind to membranes. We therefore propose that membrane association and multimerization of
HIV
-1 Gag proteins, rather than a specific motif within Gag, trigger recognition by the cellular ubiquitination machinery.
...
PMID:Ubiquitination of human immunodeficiency virus type 1 Gag is highly dependent on Gag membrane association. 1760 72
CXCR4-using
HIV
-1 was previously shown to replicate more efficiently in a healthy donor-derived CD4(+) CD38(+) than in a CD4(+) CD38(-) T-cell subset after stimulation with interleukin (IL)-4. Here, we identified 3 cellular genes, which were expressed to a higher level in an IL-4-stimulated CD38(-) subset. One of the 3 genes, RNF125/TRAC-1, was involved in the down-regulation of
HIV
-1 replication not only in cell lines, but also in peripheral blood mononuclear cells. RNF125/TRAC-1 bears the RING finger domain, important for E3
ubiquitin
protein ligase. Mutations in this domain of RNF125/TRAC-1 led to the loss of
HIV
-1 down-modulatory activity, suggesting that E3 ligase activity is necessary. In addition, the results of Northern blotting and reporter gene analysis indicated that RNF125/TRAC-1 function occurs at the viral transcription step. These results suggest that RNF125/TRAC-1 could function to recruit host factor(s) controlling
HIV
-1 transcription to the
ubiquitin
-proteasome pathway.
...
PMID:The RING finger ubiquitin ligase RNF125/TRAC-1 down-modulates HIV-1 replication in primary human peripheral blood mononuclear cells. 1764 63
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>